Y ang Ying is a key director and investor in Xiamen Amoytop Biotech, a biopharmaceutical company she helped build alongside her husband, Lan Chun, who serves as chairman. Founded in 1996, the company focuses on the R&D and commercialization of recombinant protein drugs, particularly in the fields of viral hepatitis and immunology. Their flagship product is a long-acting interferon used for treating Hepatitis B.

Yang holds a doctorate and has a background in research, contributing to the company's scientific foundation. Xiamen Amoytop Biotech successfully listed on the Shanghai STAR Market in 2020, significantly boosting the couple's wealth. Yang Ying remains actively involved in the company's governance, supporting its mission to develop innovative biological therapies for chronic diseases.